EACH LUCININTED CAPSULES CONTAINS:
Nintedanib Capsules…………………….100mg
Nintedanib Capsules…………………….150mg
INDICATIONS
LuciNinted is indicated for the treatment of idiopathic pulmonary fibrosis (IPF). LuciNinted is also indicated for the treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype. Additionally, LuciNinted is indicated to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).
DOSAGE
Recommended Dosage
The recommended dosage of LuciNinted is 150 mg administered orally twice daily approximately 12 hours apart.
Dosage Modifications for Adverse Reactions
Management of Adverse Reactions:
- Dosage reduction to 100 mg twice daily or treatment interruption may be required for the management of adverse reactions
- If a dose of LuciNinted is missed, the next dose should be taken at the next scheduled time; advise patients not to make up for a missed dose
- Discontinue LuciNinted in patients unable to tolerate 100 mg twice daily
Specific Dosage Modifications:
- For elevated liver enzymes (ALT or AST) with liver enzyme elevations >3 times the upper limit of normal (ULN): Interrupt treatment or reduce to 100 mg twice daily
- For elevated liver enzymes >5 times ULN: Discontinue LuciNinted
- Gastrointestinal reactions: Symptomatic treatment with adequate hydration is recommended; may require treatment interruption and dosage reduction or discontinuation
- For diarrhea, nausea, or vomiting not controlled with adequate supportive care: dose reduction to 100 mg twice daily or treatment interruption may be required
Administration Instructions
- LuciNinted should be taken with food
- Swallow capsules whole with liquid
- Do not chew or crush capsules
STORAGE
Store at 20℃ to 25℃ (68℉ to 77℉), excursions permitted between 15℃ and 30℃ (59℉ and 86℉) [see USP Controlled Room Temperature]. Protect from moisture.
MANUFACTURED AND MARKETED BY
LUCIUS PHARMACEUTICALS(LAO) CO., LTD
Address: Thongmang village, Xaythany district, Vientiane Capital, Laos
Original article, if reprinted, please indicate the link to this article: https://lucius-pharmaceuticals.com/drug/nintedanib-capsules/
Related News
-
RASONQUE™ (Daraxonrasib) Clinical Trials, Distribution & Value in Precision Oncology
Clinical Trials of RASONQUE™ (Daraxonrasib) The clinical development of RASONQUE™ (Daraxonrasib) has…
2026-10-05
-
RASONQUE™(Daraxonrasib): Dosage Instructions, Side Effects, FAQ & Myths
How to Take RASONQUE™ (Daraxonrasib) Safely and Effectively Take it exactly as…
2026-10-03
-
Turning Off the Signal That Fuels Cancer: RASONQUE™ (Daraxonrasib) Overview
Turning Off the Signal That Fuels Cancer: RASONQUE™ (Daraxonrasib) Overview When Every…
2026-10-01
-
Understanding ATTR-CM: A Patient-Friendly Guide to Transthyretin Amyloidosis Cardiomyopathy
1. Experience: What Living with ATTR-CM Can Feel Like Symptoms of ATTR-CM…
2026-09-04
-
LuciOdevi FAQs, Myths, Clinical‑Trial Data & Medication Distribution Guide | Lucius Pharmaceuticals
Frequently Asked Questions About LuciOdevi Q1. What is LuciOdevi?A: LuciOdevi is an…
2026-08-14
-
Unveiling New Possibilities in the Treatment of Cholestatic Liver Disorders: LuciOdevi 400mcg Developed by Lucius Pharmaceuticals
Introduction Cholestatic liver disorders cover a broad, hard‑to‑treat group of hepatobiliary illnesses…
2026-08-11



